| abstract |
The present invention relates to a novel compound having the ability to inhibit the 11β-HSD1 enzyme or to a pharmaceutically acceptable salt thereof, to a method for producing same, and to a pharmaceutical composition containing same as an active ingredient. The compound according to the present invention selectively inhibits the activity of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), and can thus be effectively used as a therapeutic agent for treating diseases caused by the excessive activity of 11β-HSD1, e.g. non-insulin dependent (type 2) diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, and diseases and conditions brought on by the excessive activity of glucocorticoids. |